A Single Dose Study to Assess the Effect of Non-Bioenhanced, Non-Enteric Coated, Freebase SB-659032 on Platelet Function in Healthy Adult Subjects
Latest Information Update: 25 Aug 2023
At a glance
- Drugs Rilapladib (Primary)
- Indications Atherosclerosis
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 01 May 2015 New trial record